Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16250620 | 0.92 | CA12 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1035839 | 0.81 | TSHR (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1037229 | 0.80 | CA12 (0.45) | CA12CA1CA2CA7CA9 | |
| Benzene SCHEMBL28834320 | 0.78 | CA12 (0.64) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9170480 | 0.78 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3306485 | 0.76 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL691161 | 0.76 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12956479 | 0.76 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7865371 | 0.74 | CA12 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL274749 | 0.74 | CA12 (0.58) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451847-B1 | POLYMER-BOUND BISACYLPHOSPHINE OXIDES | IGM GROUP B V (NL) | 2021-11-24 | — | — | EP | disclosed |
| US-10023675-B2 | Polymer nanoparticles | ETH ZUERICH (CH) | 2018-07-17 | — | — | US | disclosed |
| US-10023675-B2 | Polymer nanoparticles | ETH ZUERICH (CH) | 2018-07-17 | — | — | US | disclosed |
| US-10023675-B2 | Polymer nanoparticles | ETH ZUERICH (CH) | 2018-07-17 | — | — | US | disclosed |
| US-20160024241-A1 | POLYMER NANOPARTICLES | ETH ZUERICH (CH) | 2016-01-28 | — | — | US | disclosed |
| US-20160024241-A1 | POLYMER NANOPARTICLES | ETH ZUERICH (CH) | 2016-01-28 | — | — | US | disclosed |
| US-20160024241-A1 | POLYMER NANOPARTICLES | ETH ZUERICH (CH) | 2016-01-28 | — | — | US | disclosed |
| US-9181358-B2 | Polymer nanoparticles | ETH ZUERICH (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9181358-B2 | Polymer nanoparticles | ETH ZUERICH (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9181358-B2 | Polymer nanoparticles | ETH ZUERICH (CH) | 2015-11-10 | — | — | US | disclosed |
| US-8883872-B2 | Polymer-bound bisacylphosphine oxides | BASF SE (DE) | 2014-11-11 | — | — | US | disclosed |
| US-20120142805-A1 | POLYMER-BOUND BISACYLPHOSPHINE OXIDES | BASF SE (DE) | 2012-06-07 | — | — | US | disclosed |
| EP-2451847-A1 | POLYMER-BOUND BISACYLPHOSPHINE OXIDES | BASF SE (DE) | 2012-05-16 | — | — | EP | disclosed |
| US-20120115963-A1 | POLYMER NANOPARTICLES | ETH ZUERICH (CH) | 2012-05-10 | — | — | US | disclosed |
| US-20120115963-A1 | POLYMER NANOPARTICLES | ETH ZUERICH (CH) | 2012-05-10 | — | — | US | disclosed |
| US-20120115963-A1 | POLYMER NANOPARTICLES | ETH ZUERICH (CH) | 2012-05-10 | — | — | US | disclosed |
| EP-2421903-A1 | POLYMER NANOPARTICLES | ETH Zurich (CH) | 2012-02-29 | — | — | EP | disclosed |
| WO-2011003772-A1 | POLYMER-BOUND BISACYLPHOSPHINE OXIDES | BASF SE (DE) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010121387-A1 | POLYMER NANOPARTICLES | ETH Zürich (CH) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010121387-A1 | POLYMER NANOPARTICLES | ETH Zürich (CH) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024241-A1 | POLYMER NANOPARTICLES | POLQ, POLN, POLA1 | CA12 3655/4885CA1 4348/4885CA2 4800/4885 |
| US-10023675-B2 | Polymer nanoparticles | POLQ, POLN, POLA1 | CA12 3655/4885CA1 4348/4885CA2 4800/4885 |
| US-20120115963-A1 | POLYMER NANOPARTICLES | POLQ, POLN, POLA1 | CA12 3655/4885CA1 4348/4885CA2 4800/4885 |
| US-20120142805-A1 | POLYMER-BOUND BISACYLPHOSPHINE OXIDES | PHOSPHO1, PARG, PEBP1 | CA12 3756/4885CA1 3586/4885CA2 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.